Why the study?
Does trimetazidine provide cardio- and cytoprotective benefits for the long-term treatment of hypertrophic cardiomyopathy compared to classic drugs?
Does trimetazidine provide cardio- and cytoprotective benefits for the long-term treatment of hypertrophic cardiomyopathy compared to classic drugs?
This review discusses the potential of trimetazidine as a long-term treatment for hypertrophic cardiomyopathy based on its cardio- and cytoprotective properties.
Answers are grounded in this paper and cite their sources.
No change to HCM care warranted; leaves open trimetazidine's long-term role pending prospective trials.
In this review we consider available information on the cardio- and cytoprotective properties and mechanism of action of trimetazidine, an antianginal drug. Two points in particular are addressed: the advantages of trimetazidine over classic drugs and its possible use for the long-term treatment of hypertrophic cardiomyopathy, described as an ischemic disorder.
No takes yet. Share an insight, caveat, or question.
Nathalie Picollet-D’hahan (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: